



Department
of Health

Medicaid NYRx

NYRx Education & Outreach MCO Newsletter

[Highlights](#) | [Publications](#) | [Quicklinks](#) | [About](#) | [Weekly Webinars](#) | [Contact](#)

August 2026

Highlights

Cost Optimization Program Update: Program Additions

The NYRx, Medicaid Pharmacy cost optimization program helps address increasing drug costs. This program focuses on a specific drug trend that is primarily occurring with new formulations and dosages of older drug products. These drugs are being manufactured and are entering the market with substantially higher launch prices than equally efficacious, cost-effective alternatives.

Effective **July 16, 2026**, the following **drugs** will be **added** to the Cost-optimization program **and will require a Manual Review by NYRx** for coverage approval:

- | | |
|---|---|
| <ul style="list-style-type: none">• cephalexin 750 mg capsule, 250 mg, 500 mg tablet• clindamycin/benzoyl peroxide 1.2%-3.75% gel• clindamycin phosphate 1% foam• clindamycin/tretinoin 1.2%-0.025% gel• clonidine hcl 0.05 mg tablet• dexamethasone 0.25 mg tablet• doxycycline monohydrate 75 mg, 150 mg capsule• Fenofibrate 50 mg, 150 mg capsule (Lipofen)• fenoprofen 400 mg capsule; Fenoprofen 600 mg tablet (Nalfon) | <ul style="list-style-type: none">• folic acid 0.2 mg/mL solution (Quiofic)• glipizide 15 mg tablet• granisol 2 mg/10 mL solution• halobetasol 0.05% foam• indomethacin 25 mg/5 mL suspension• ketoprofen 200 mg ER capsule• Neo-Synalar 0.5%-0.025% cream• tazarotene foam (Fabior)• tolmetin sodium 200 mg tablet |
|---|---|

For the full, most up-to-date list, see [NYRx, the Medicaid Pharmacy Cost Optimization Program Updates](#).



[Top ↑](#)

NYRx Brand Less Than Generic Program Update

Effective **July 16, 2026**, the following changes were made to the Dispense Brand Name Drug When Less Expensive Than the Generic Program:



- **Bosulif® tablet, Janumet®, Januvia®, and Xyrem®** were **ADDED** to the program.
- **Farxiga® and Ravicti®** were **REMOVED** from the program.

In conformance with State Education Law, a pharmacist shall dispense a less expensive, therapeutically equivalent drug containing the same active ingredients, dosage form, and strength as the drug prescribed/ordered.


For further information, see the [NYRx Brand Less Than Generic Program Update](#).



[Top ↑](#)

Discontinued Drug Coverage for Terminated Labelers per the Medicaid National Drug Rebate Agreement

Effective **July 1, 2026**, the following drug manufacturers voluntarily withdrew from participation in the Medicaid Drug Rebate Program (MDRP). As a result, NYRx, the Medicaid Pharmacy Program, will no longer provide coverage for drugs manufactured by the manufacturers listed below.



NDC (Labeler code)	Manufacturer Name
69853	ALEXION PHARMACEUTICALS, INC
69660	CLOVIS ONCOLOGY, INC
73079	EIGER BIOPHARMACEUTICALS
85633	ESTIVA GENERICS
71800	INNOVIDA PHARMACEUTIQUE CORPORATION
45861	PHARMACEUTICA NORTH AMERICA, INC
72928	Q BIOMED, INC
13925	SETON PHARMACEUTICALS, INC
54879	STI PHARMA, LLC
00941	VANTIVE US HEALTHCARE, LLC
00206	WYETH PHARMACEUTICALS, LLC
42195	XSPIRE PHARMA, LLC
69117	YILING PHARMACEUTICAL, INC
82036	ZAMBON USA, LTD

Affected products include:

- Acetaminophen-caffeine-dihydrocodeine capsule
- Acyclovir tablet
- Anastrozole tablet
- Buspirone tablet
- Butalbital-acetaminophen capsule
- Butalbital-acetaminophen-caffeine capsule
- Celecoxib capsule
- Ciprofloxacin fluocinolone otic
- Ciprofloxacin otic solution and tablet
- Clopidogrel tablet
- Dapsone tablet
- Dexamethasone tablet
- Diphenhydramine solution
- Docusate sodium gelcap
- Doxycycline tablet
- Escitalopram tablet
- Ethambutol tablet
- Felodipine tablet
- Fenoprofen capsule and tablet
- Letrozole tablet
- **Levamlodipine tablet***
- Lidocaine cream
- Memantine solution
- Nalfon capsule and tablet
- Pentamidine inhalation and injectable
- Polyethylene glycol powder
- Prednisolone solution
- Sennosides tablet

*Except for the drug notated, there are alternate NDC's from other manufacturers available.

For more information, see [Discontinued Drug Coverage for Terminated Labelers per the Medicaid National Drug Rebate Agreement](#).



Publications

Click to access [NYRx, the Medicaid Pharmacy Program](#) website for these publications and more:

- Billing & Coordination of Benefits
- Drug Class Coverage Overviews
- Newsletters
- Notifications
- Prior Authorization Information

[Top ↑](#)

Quicklinks



[NYRx Preferred Drug List](#)



[NYRx Preferred Drug Quick List](#)



[NYRx eMedNY Formulary File](#)



[NYRx Brand Less Than Generic Program Updates](#)



[NYRx Preferred Diabetic Supply Program](#)

[Top ↑](#)

About the NYRx E&O Team

The NYRx E&O team serves as a liaison between all stakeholders and NYRx to support care coordination. Clinical liaisons are trained to support and help solve complex pharmacy cases for:



- Managed Care Plans
- Case workers and NYS agencies
- Prescribers and pharmacies with questions regarding NYRx drug coverage, prior approval requirements, and NYRx enrolled pharmacies
- Complex care coordination for populations such as HIV/AIDS, Hemophilia, Foster Care Children, Serious Mental Illness, Substance Use Disorder, and Hepatitis C

[Top ↑](#)

Weekly Webinars

To register, please visit the [NYRx Education & Outreach](#) website.

Prescriber Webinar

Mondays

12 PM – 1 PM ET

Pharmacy Webinar

Wednesdays

12 PM – 1 PM ET

NYRx, the Medicaid Pharmacy Program

Fridays

12 PM – 1 PM ET

[Top ↑](#)

Contact Us

Office Hour Q&A Pop-In

Mondays and Wednesdays

12 PM – 1 PM ET

[Click here to join.](#)



Meet with the Team

The NYRx E&O team meets with various stakeholders throughout the month.

Would you like to request a meeting with us? Click [here](#).

NYRx E&O Call Center

1-833-967-7310

Monday – Friday

8 AM – 5 PM ET

Excludes Holidays



[Top ↑](#)



[Website](#)



[Email](#)



[NYRx E&O Channel](#)



[NYS Public Health Now Podcast](#)